HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) qualification for weight loss depends on specific medical criteria established by FDA guidance and clinical practice standards. Most candidates have a BMI of 30 or higher, or BMI of 27+ with weight-related comorbidities such as hypertension, type 2 diabetes, or sleep apnea.

Understanding eligibility goes beyond meeting minimum BMI thresholds. A qualified healthcare provider evaluates your metabolic health, medication history, and individual risk profile to determine whether GLP-1 therapy aligns with evidence-based treatment principles.

Core Medical Eligibility Criteria for GLP-1 Receptor Agonist Therapy

The FDA-approved weight-loss indication for semaglutide requires either a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related condition. Weight-related comorbidities include hypertension, type 2 diabetes, cardiovascular disease, or obstructive sleep apnea.

Beyond BMI thresholds, providers evaluate your medical history for contraindications. Personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pancreatitis, gallbladder disease, and severe kidney or liver disease warrant careful discussion with your physician before starting therapy.

Provider-Guided Assessment Framework: Key Medical Factors

Healthcare providers use a structured assessment to determine GLP-1 candidacy. This framework considers not just weight metrics, but metabolic markers, treatment history, and individual risk tolerance to support informed decision-making.

Assessment Factor What Providers Evaluate
BMI and Weight History Current BMI (≥30 or ≥27 with comorbidity), weight loss attempts, rate of weight gain
Metabolic Comorbidities Type 2 diabetes, hypertension, lipid profile, cardiovascular risk, sleep apnea
Medication Interactions Current medications, contraindications, kidney and liver function
Gastrointestinal Health History of pancreatitis, gallbladder disease, gastroparesis, inflammatory bowel disease
Psychological Readiness Commitment to lifestyle modification, understanding of side effects, mental health support

Role of Biomarkers in Individualizing GLP-1 Selection

Beyond eligibility criteria, biomarkers provide additional context for treatment optimization. Fasting glucose, HbA1c, lipid panels, and inflammatory markers can help providers understand your metabolic baseline and track response to therapy over time.

Genetic factors affecting GLP-1 pathway sensitivity—such as variations in GLP1R, GIPR, and FTO genes—may influence individual medication tolerance and efficacy patterns. This information may help provide context for provider discussions about which GLP-1 formulation or dosing strategy could align with your individual physiology.

When GLP-1 Therapy May Not Be Appropriate: Safety Considerations

Certain medical conditions represent relative or absolute contraindications to GLP-1 therapy. Personal or family history of medullary thyroid cancer, active pancreatitis, severe kidney disease (eGFR <15), decompensated liver cirrhosis, and uncontrolled blood pressure require specialist consultation before proceeding.

Pregnancy, breastfeeding, recent abdominal surgery, and planned bariatric surgery warrant discussion with your provider. Side effects such as nausea, vomiting, dehydration, and gallbladder complications occur in a subset of patients and should be weighed against potential benefits during your eligibility assessment.

How PlexusDx Supports a More Personalized Approach

PlexusDx supports precision assessment through the Precision Peptide Genetic Test, which reveals predispositions in GLP-1 and other peptide pathway genes. Testing for variants in GLP1R, GIPR, FTO, and MC4R may help provide context about your individual metabolic and appetite-regulation pathways—information that can inform a more personalized conversation with your provider about whether compounded or branded GLP-1 options align with your genetic profile.

The genetic test does not predict exact medication response or guarantee outcomes. Instead, it identifies predispositions that may correlate with baseline metabolic characteristics and pathway sensitivity. These insights should be interpreted with a qualified healthcare provider who can integrate genetic context with clinical assessment, biomarkers, and your full medical history.

Understanding your genetic predispositions alongside standard clinical criteria creates a more complete eligibility picture. Patients with higher genetic predisposition scores for GLP-1 pathway sensitivity may benefit from earlier or more aggressive treatment consideration, while those with lower scores might explore alternative or adjunctive strategies first.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.